217 related articles for article (PubMed ID: 30974435)
21. Loss-of-function but not dominant-negative intragenic
Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
[TBL] [Abstract][Full Text] [Related]
22. COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia.
Lopes BA; Meyer C; Barbosa TC; Zur Stadt U; Horstmann M; Venn NC; Heatley S; White DL; Sutton R; Pombo-de-Oliveira MS; Marschalek R; Emerenciano M
Oncotarget; 2016 Aug; 7(33):53064-53073. PubMed ID: 27419633
[TBL] [Abstract][Full Text] [Related]
23. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.
Cazzaniga G; van Delft FW; Lo Nigro L; Ford AM; Score J; Iacobucci I; Mirabile E; Taj M; Colman SM; Biondi A; Greaves M
Blood; 2011 Nov; 118(20):5559-64. PubMed ID: 21960589
[TBL] [Abstract][Full Text] [Related]
24. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
[TBL] [Abstract][Full Text] [Related]
25. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G
Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361
[TBL] [Abstract][Full Text] [Related]
26. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
Kim M; Park J; Kim DW; Kim YJ; Jeon YW; Yoon JH; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim HJ; Min CK; Cho SG; Kim Y; Lee JW; Han K; Min WS; Lee S
Bone Marrow Transplant; 2015 Mar; 50(3):354-62. PubMed ID: 25501350
[TBL] [Abstract][Full Text] [Related]
27. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
28. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
29. [Effect of increasing the intensity of chemotherapy on the prognosis of acute lymphoblastic leukemia in children with IKZF1 deletion].
Zheng YZ; Li J; LE SH; Zheng H; Hua XL; Chen ZS; Hu JD
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jul; 21(7):690-695. PubMed ID: 31315770
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
[TBL] [Abstract][Full Text] [Related]
31. Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.
Dong Y; Liu F; Wu C; Li S; Zhao X; Zhang P; Jiao J; Yu X; Ji Y; Zhang M
Clin Exp Immunol; 2016 Sep; 185(3):320-31. PubMed ID: 27198500
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
33. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
[TBL] [Abstract][Full Text] [Related]
34. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.
Huang Z; Jia Y; Ruan G; Zuo Y; Wu J; Lu A; Xue Y; Cheng Y; Zhang L
Pediatr Hematol Oncol; 2022 Apr; 39(3):243-253. PubMed ID: 34582325
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
37. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
38. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract][Full Text] [Related]
40. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.
Olsson L; Castor A; Behrendtz M; Biloglav A; Forestier E; Paulsson K; Johansson B
Leukemia; 2014 Feb; 28(2):302-10. PubMed ID: 23823658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]